Preserve Muscle on GLP-1: A Peptide Stack Protocol

The Pickle Jar

This is the part of GLP-1 therapy that the original prescription conversation rarely covers in depth. The weight loss works. The appetite suppression works. The metabolic improvements are real. And underneath all of that, the body is losing lean mass at a faster clip than it would on any other weight-loss intervention because the loss happens too fast for protein synthesis to keep up.

PeRx Does Not Prescribe GLP-1s

Before going further, the framing this guide is built on: PeRx does not prescribe semaglutide, tirzepatide, or any other GLP-1 receptor agonist. The peptide stack covered here is not a GLP-1 alternative, is not a "natural Ozempic," and should not be substituted for an active GLP-1 prescription if your provider has put you on one for a clinical indication.

What this stack is: the recovery and adaptation layer that sits underneath GLP-1 therapy. When patients lose 15 to 25% of body weight on GLP-1 medications, roughly one-quarter to one-third of that loss is lean mass, and the peptides most studied for offsetting it work on different axes. Tesamorelin and CJC-1295/Ipamorelin stimulate endogenous growth hormone. BPC-157 supports tendon and joint recovery so resistance training is tolerable as you resume it. MOTS-c targets mitochondrial efficiency through the metabolic recovery window. NAD+ supports cellular energy during the training restart.

This guide assumes you already have the GLP-1 conversation handled with your prescribing physician. What follows is the protocol depth on the peptide side: which peptide does what, when it goes into the rotation, and the 12-week recomposition arc that PeRx providers most often see work. For background on the lean mass loss problem itself, see our companion piece on how to keep muscle while taking Ozempic, Wegovy, or Mounjaro, and the transition guide coming off Ozempic.

The Math of Muscle Loss on GLP-1

Across published clinical studies and meta-analyses since 2023, roughly 15 to 40% of the weight lost on GLP-1 medications is lean mass rather than fat. The variance is wide because the protective factors (resistance training, adequate protein intake, baseline muscle mass, age) make a significant difference. The math, for a person losing 50 pounds on GLP-1 therapy over 12 months: somewhere between 7.5 and 20 pounds of that loss is lean tissue. For an older patient with already-modest baseline muscle, the higher end of that range is where most of them land without intervention.

The mechanism is not unique to GLP-1s. Any rapid weight loss produces some lean mass loss. What is specific to GLP-1 therapy is the speed of the loss and the simultaneous appetite suppression that makes the standard countermeasure (eating more protein) harder to execute. Patients on Ozempic, Wegovy, Mounjaro, or Zepbound often find they are eating 60-70% of the protein they used to, at exactly the moment the body needs more.

The downstream effect is the pickle-jar moment. Grip strength declines because forearm and hand muscle declines. Stair-climbing capacity declines because quad and glute mass declines. Bone density risk increases because lean mass and bone mass track together. Resting metabolic rate drops because skeletal muscle is the largest metabolically active tissue. The labs may look good and the scale may look great, but the functional capacity is being quietly hollowed out.

Why Protein and Lifting Alone Often Is Not Enough

The standard advice for lean mass preservation in any weight loss context is the same: eat 1.6 g of protein per kg of body weight or more, train resistance 3-4x weekly, prioritize sleep. That advice is correct, and it is the foundation. For most adults losing weight at a moderate pace (1-2 pounds per week, traditional calorie deficit), it is enough.

On GLP-1 therapy, the foundation gets harder to execute and is less sufficient when you do. Appetite suppression means hitting 1.6 g/kg of protein requires deliberate effort that most patients underestimate. Reduced caloric intake reduces training capacity, so the gym sessions get shorter and less productive. The pace of weight loss is faster than the pace of protein synthesis can keep up with, even when the protein intake is technically adequate. And many GLP-1 patients are in age brackets (45+) where the baseline protein utilization is already lower than in their 20s.

The peptide stack does not replace the foundation. The protein and the lifting are still upstream of everything else. What the stack does is signal the body to direct more of the available protein toward lean mass retention, support the recovery machinery so the resistance training you can manage is more productive, and protect the GH-axis that does most of the overnight tissue repair work. Foundation first, peptides on top.

Tesamorelin: Visceral Fat and Lean Mass

Tesamorelin is a synthetic GHRH (growth hormone-releasing hormone) analog that stimulates the pituitary to produce more endogenous growth hormone. It is the most clinically validated peptide in the post-GLP-1 stack because it has a full FDA approval (under the brand name Egrifta) for HIV-associated visceral lipodystrophy. The mechanism that works there (visceral fat reduction with lean mass preservation through GH stimulation) is the same mechanism that maps onto post-GLP-1 recomposition.

For patients with elevated visceral adiposity (waist circumference over 40 inches in men or over 35 inches in women, or measured visceral fat above clinical thresholds), Tesamorelin is the most-cited peptide in this category. The published Egrifta data shows roughly 15-18% visceral fat reduction over 26 weeks of consistent dosing, with simultaneous preservation of subcutaneous tissue and lean mass. Whether that magnitude translates to the post-GLP-1 patient population specifically is still being characterized in the literature, but the mechanism alignment is strong.

Practical use in this stack: Tesamorelin is dosed nightly, subcutaneous injection, typically in the abdomen. It works on a multi-week timeline (8-12 weeks before the visceral fat and lean mass effects show up subjectively, longer for the body composition scans to confirm). For most patients in the post-GLP-1 window, Tesamorelin starts in the maintenance phase of GLP-1 therapy rather than at the GLP-1 initiation, so the GH-axis support is in place before the taper begins.

CJC-1295/Ipamorelin: The GH Pulse During the Deficit

CJC-1295/Ipamorelin is the GH-releasing peptide combination most commonly used for general lean mass preservation, including in the post-GLP-1 context. CJC-1295 extends the half-life of the GHRH signal so the GH pulse lasts longer than the body would produce on its own. Ipamorelin stimulates GH release through the ghrelin receptor pathway without raising cortisol or prolactin, which is a cleaner profile than older GHRPs.

For post-GLP-1 patients, CJC-1295/Ipamorelin is the workhorse of the lean mass side. It supports the natural overnight GH pulse during sleep, which is when most lean mass-protective tissue repair happens. Patients running the stack typically report better sleep quality within the first 2-3 weeks, with the body composition changes (improved lean-to-fat ratio, particularly visible in the morning waist measurement) showing up over 8-12 weeks.

For more on why we pair CJC-1295 with Ipamorelin specifically rather than using either alone, see our pairing rationale. The short version: the GHRH (CJC-1295) and the ghrelin-mimetic (Ipamorelin) work on different pituitary receptors, so the combined GH pulse is more sustained and physiologically cleaner than either alone.

Practical use: subcutaneous injection, typically before bed on an empty stomach (the GH pulse is most effective when not competing with a postprandial insulin spike). The dosing cadence depends on the patient profile; common patterns are 5-on, 2-off, or 3x weekly during the active recomposition window.

BPC-157: Joints and Tendons for Resumed Training

BPC-157 is the most-studied tissue repair peptide, with 100+ preclinical studies from the University of Zagreb over 30 years primarily on soft tissue and gut healing. In the post-GLP-1 context, its role is the joint and tendon support that makes resistance training tolerable as you resume it.

The pattern most patients run into: 6-12 months on a GLP-1, training volume dropped substantially because you were tired and not eating much, weight came off but so did training capacity. When the taper begins or the maintenance dose feels manageable enough to train again, the joints and tendons that have been deconditioned for a year are not ready for the load you used to handle. The Achilles barks. The patellar tendon flares. The right shoulder from the bench press complains about a weight that used to feel light.

BPC-157 daily during the first 8-12 weeks of resumed training is the most common pattern. The mechanism (VEGF upregulation for new blood vessel growth into tissue, fibroblast modulation for collagen deposition, nitric oxide pathway support) aligns with what reconditioning tendons and joints actually need. It will not let you skip the deconditioning. It will make the climb back to your prior training capacity less injury-prone.

MOTS-c: Mitochondrial Recovery

MOTS-c is a mitochondrial-encoded peptide discovered at USC in 2015. It is the newest peptide in clinical use and the only one in this stack with a mechanism aimed specifically at mitochondrial function. In animal models, it improves insulin sensitivity, increases fat oxidation, and acts as an exercise mimetic.

For post-GLP-1 patients, MOTS-c maps onto the metabolic recovery window. Extended caloric restriction (which is what GLP-1 therapy effectively is, even if the suppression is appetite-driven rather than willpower-driven) reduces mitochondrial efficiency. The cellular engines that produce ATP downregulate when fuel is chronically scarce. When the GLP-1 tapers and caloric intake normalizes, the mitochondrial machinery has to ramp back up, and MOTS-c is the peptide most directly aimed at that ramp.

Practical use: subcutaneous injection, typically 2-3x weekly at maintenance dose during the recomposition window. The subjective effects (improved aerobic feel on cardio, faster recovery between training sessions, less metabolic fatigue across the week) typically take 3-6 weeks to show up. MOTS-c is the most appropriate peptide in this stack for the patient who is also a runner, cyclist, or endurance athlete returning to training.

NAD+: Cellular Energy for the Training Restart

NAD+ is a coenzyme every cell uses to convert food into ATP. Tissue NAD+ levels drop with age (roughly 50% decline by middle age) and drop further under sustained caloric restriction. For post-GLP-1 patients restarting training, NAD+ supports the cellular energy production that makes training sessions productive rather than draining.

Injectable NAD+ bypasses the GI conversion limits that cap how much oral NMN or NR can actually raise tissue levels. A common pattern in the post-GLP-1 protocol is NAD+ 2-3x weekly at maintenance dose, with a higher dose at the start of the recomposition window when training capacity is lowest. The most reported effect: the 4 p.m. energy fade that built up across the GLP-1 months becomes manageable without coffee, and training sessions feel like training sessions rather than survival events.

NAD+ also pairs cleanly with the other peptides in the stack. There are no documented interactions with Tesamorelin, CJC-1295/Ipamorelin, BPC-157, or MOTS-c. For more on how NAD+ compares to its often-confused cousin Glutathione, see our NAD+ vs Glutathione comparison.

The 12-Week Post-GLP-1 Recomposition Protocol

The protocol that PeRx providers most often see work, in the post-GLP-1 recomposition window. This is a starting framework; the prescribing provider tunes it based on your bloodwork, training capacity, and how you respond in the first few weeks.

What This Protocol Will Not Do

The peptide stack is often confused with several things it is not. Five honest distinctions.

Not a GLP-1 alternative. The peptides in this stack do not produce GLP-1-like weight loss, do not suppress appetite, and do not affect glycemic control. They address a different layer of the same patient experience. If you need a GLP-1 for clinical reasons, the peptide stack does not replace it.

Not a substitute for protein and resistance training. The protein and the lifting are still the foundation. The peptides signal the body to do more with the available protein and recover better from the available training. They do not produce lean mass from nothing.

Not a guarantee of zero lean mass loss. The protocol reduces the percentage of weight loss that comes from lean tissue. It does not eliminate the effect. Some lean mass loss is expected with any rapid weight loss, including on this stack.

Not a permission slip to skip the GLP-1 conversation with your prescribing physician. Any change to GLP-1 dosing, taper timing, or cessation is a conversation with the doctor who prescribed it. The peptide stack runs alongside that decision, not instead of it.

Not a fountain of youth or a body recomposition shortcut for non-GLP-1 patients. The stack is built for the specific physiological situation of GLP-1-induced lean mass loss. For patients who have not been on GLP-1 therapy, the same peptides exist but the stacking logic is different. See our best peptides for recovery page for the non-GLP-1 framing.

Common Questions